Bi-specific Chimeric Antigen Receptor for TGF-beta Binding

ChangeBridge: Patent Grants - Peptides (C07K)

Published March 31st, 2026

Detected March 31st, 2026

Summary

USPTO granted patent US12590145B2 to The Regents of the University of California on March 31, 2026, covering a bi-specific chimeric antigen receptor (CAR) that specifically binds TGF-beta. The CAR technology neutralizes TGF-beta while simultaneously triggering T-cell activation, converting an immunosuppressive signal into an activating stimulus. The patent contains 10 claims with application number 17323568, filed May 18, 2021.

View original document View source feed page

What changed

USPTO granted patent US12590145B2 to The Regents of the University of California on March 31, 2026. The patent covers a bi-specific CAR comprising a signal peptide, TGF-beta binding antigen-binding domain, peptide spacer, transmembrane domain, and endodomain. Inventors are Yvonne Yu-Hsuan Chen and Zenan Li Chang. The technology enables cells to neutralize TGF-beta while triggering T-cell activation, turning immunosuppressive signals into activating stimuli for immunotherapy applications.

Entities developing TGF-beta targeting immunotherapies should assess their freedom to operate. Third parties wishing to develop or commercialize TGF-beta targeting CAR therapies may need to obtain licensing from UC. Patent grants do not impose compliance deadlines or penalties on existing market participants, but technology developers should review patent claims to ensure no infringement risk.

Source document (simplified)

← USPTO Patent Grants

Bi-specific chimeric antigen receptor

Grant US12590145B2 Kind: B2 Mar 31, 2026

Assignee

The Regents of the University of California

Inventors

Yvonne Yu-Hsuan Chen, Zenan Li Chang

Abstract

Aspects of the disclosure relate to polypeptides comprising a signal peptide, an antigen-binding domain that specifically binds TGF-β, a peptide spacer, a transmembrane domain, and an endodomain. When expressed in a cell, the polypeptides are capable of not only neutralizing the TGF-β but also specifically triggering T-cell activation in the presence of TGF-β. T-cell activation spurs the immune cell to produce immunostimulatory cytokines and proliferate, thus turning TGF-β from an immunosuppressive signal to an activating stimulus.